Europe Early Toxicity Testing Market by Technique Type (In Vivo, In Vitro, and In Silico), by Application (Drug discovery, Chemical testing and Others) and End Users (Pharmaceuticals Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Others): Opportunity Analysis and Industry Forecast, 2018 - 2025
The Europe early toxicity testing market accounted for $265 million in 2017, and is expected to reach $460 million by 2025, registering a CAGR of 7.1% from 2018 to 2025.
Toxicity is the degree of threat posed by a substance to the living organism, and toxicology is a branch of science that deals with measurement and further analysis of these chemical substances and their adverse effects on the body of an organism. The effects of chemical substances on the body are studied to choose a potential drug candidate during the development of newer molecules. Early toxicity testing is carried out at preclinical stages of a drug development process and is essential as toxicity serves as the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. Early toxicity testing can be performed using different techniques such as in vivo, in vitro, and in silico. These techniques are employed to carry out different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others.
Major factors that drive the market growth are surge in the research and development activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in vitro techniques, rise in adoption of in vitro models in the Europe early toxicity testing industry and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.
This report segments the Europe early toxicity testing market on the basis of technique, application, end users, and country to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints. Based on country, the market is studied across different countries of Europe such as Germany, France, the UK, and rest of Europe.
KEY BENEFITS FOR STAKEHOLDERS
Toxicity is the degree of threat posed by a substance to the living organism, and toxicology is a branch of science that deals with measurement and further analysis of these chemical substances and their adverse effects on the body of an organism. The effects of chemical substances on the body are studied to choose a potential drug candidate during the development of newer molecules. Early toxicity testing is carried out at preclinical stages of a drug development process and is essential as toxicity serves as the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. Early toxicity testing can be performed using different techniques such as in vivo, in vitro, and in silico. These techniques are employed to carry out different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others.
Major factors that drive the market growth are surge in the research and development activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in vitro techniques, rise in adoption of in vitro models in the Europe early toxicity testing industry and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.
This report segments the Europe early toxicity testing market on the basis of technique, application, end users, and country to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints. Based on country, the market is studied across different countries of Europe such as Germany, France, the UK, and rest of Europe.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the Europe early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
- In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the European market.
- By Technique
- In Vivo
- In Vitro
- In Vitro Toxicity Testing Market by Assays
- Enzyme Toxicity Assays
- Bacterial Toxicity Assays
- Cell-Based ELISA and Western Blots
- Tissue Culture Assays
- Receptor Binding Assays
- Other Assays
- In Vitro Toxicity Testing Market by Toxicity Endpoints
- Dermal Toxicity
- Systemic Toxicity
- Carcinogenicity
- Ocular Toxicity
- Skin Sensitization and Irritation
- Genotoxicity
- Neurotoxicity
- Organ Toxicity
- Other Toxicity Endpoints
- In Silico
- By Application
- Drug discovery
- Chemical testing
- Others
- By End User
- Pharmaceuticals Industry
- Food Industry
- Chemicals Industry
- Cosmetics Industry
- Other Industries
- By Country
- Germany
- France
- UK
- Rest of Europe
- Agilent Technologies, Inc.
- General Electric Company (GE Healthcare)
- Danaher Corporation (Beckman Coulter, Inc.)
- Evotec AG (Cyprotex)
- Bioanalytical Systems, Inc.
- Bruker Corporation
- Thermo Fisher Scientific, Inc.
- PerkinElmer Inc.
- Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
- The Jackson Laboratory
- Randox Toxicology
- Geneva Laboratories, Inc.
- Advanced Chemistry Development (ACD/Labs)
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017
3.3. Top player positioning, 2017
3.4. Porter’s five forces analysis
3.5. Government Regulations
3.6. Market Dynamics
3.6.1. Drivers
3.6.1.1. Surge in research and development activities in healthcare
3.6.1.2. Rise in adoption of vitro model
3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
3.6.1.4. Surge in adoption of early toxicity testing
3.6.2. Restraints
3.6.2.1. Limitations of preclinical testing
3.6.3. Opportunities
3.6.3.1. Technological advancement in the field of early toxicity testing
3.6.4. Impact Analyses
CHAPTER 4: EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
4.1. Overview
4.1.1. Market size and forecast
4.2. In Vivo
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by country
4.3. In Vitro
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by country
4.3.3. In Vitro Early Toxicity Testing Market, By Assay
4.3.3.1. Enzyme toxicity assays
4.3.3.1.1. Market size and forecast
4.3.3.2. Bacterial toxicity assays
4.3.3.2.1.1. Market size and forecast
4.3.3.3. Cell-Based ELISA and Western Blots
4.3.3.3.1.1. Market size and forecast
4.3.3.4. Tissues Culture Assays
4.3.3.4.1.1. Market size and forecast
4.3.3.5. Receptor Binding Assays
4.3.3.5.1.1. Market size and forecast
4.3.3.6. Other Assays
4.3.3.6.1.1. Market size and forecast
4.3.4. In Vitro Early Toxicity Testing Market, By Toxicity End-Points
4.3.4.1. Dermal Toxicity
4.3.4.1.1.1. Market size and forecast
4.3.4.1.1.2. Market size and forecast, by end user
4.3.4.2. Systemic toxicity
4.3.4.2.1.1. Market size and forecast
4.3.4.2.1.2. Market size and forecast, by end user
4.3.4.3. Carcinogenicity
4.3.4.3.1.1. Market size and forecast
4.3.4.4. Ocular toxicity
4.3.4.4.1.1. Market size and forecast
4.3.4.4.1.2. Market size and forecast, by end user
4.3.4.5. Skin sensitization and irritation
4.3.4.5.1.1. Market size and forecast
4.3.4.6. Genotoxicity
4.3.4.6.1.1. Market size and forecast
4.3.4.7. Neurotoxicity
4.3.4.7.1.1. Market size and forecast
4.3.4.8. Organ toxicity
4.3.4.8.1.1. Market size and forecast
4.3.4.9. Other toxicity endpoints
4.3.4.9.1.1. Market size and forecast
4.4. In Silico
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by country
CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Medical
5.2.1. Market size and forecast, by type
5.2.1.1. Examination
5.2.1.1.1. Market size and forecast
5.2.1.2. Surgical
5.2.1.2.1. Market size and forecast
5.2.2. Market size and forecast, by country
5.3. Non-Medical
5.3.1. Market size and forecast, by type
5.3.1.1. Food services
5.3.1.1.1. Market size and forecast
5.3.1.2. Clean Room
5.3.1.2.1. Market size and forecast
5.3.1.3. Industrial
5.3.1.3.1. Market size and forecast
5.3.2. Market size and forecast, by country
CHAPTER 6: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pharmaceutical Industry
6.2.1. Market size and forecast, by country
6.3. Diagnostics Industry
6.3.1. Market size and forecast, by country
6.4. Food Industry
6.4.1. Market size and forecast, by country
6.5. Chemicals Industry
6.5.1. Market size and forecast, by country
6.6. Cosmetic Industry
6.6.1. Market size and forecast, by country
6.7. Other Industries
6.7.1. Market size and forecast, by country
CHAPTER 7: EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY
7.1. Overview
7.1.1. Key market trends, growth factors, and opportunities
7.1.2. Market size and forecast, by country
7.1.2.1. Germany
7.1.2.1.1. Germany market size and forecast, by technique
7.1.2.1.2. Germany market size and forecast, by application
7.1.2.1.3. Germany market size and forecast, by end user
7.1.2.2. France
7.1.2.2.1. France market size and forecast, by technique
7.1.2.2.2. France market size and forecast, by application
7.1.2.2.3. France market size and forecast, by end user
7.1.2.3. UK
7.1.2.3.1. UK market size and forecast, by technique
7.1.2.3.2. UK market size and forecast, by application
7.1.2.3.3. UK market size and forecast, by end user
7.1.2.4. Rest of Europe
7.1.2.4.1. Rest of Europe market size and forecast, by technique
7.1.2.4.2. Rest of Europe market size and forecast, by application
7.1.2.4.3. Rest of Europe market size and forecast, by end user
7.1.3. Market size and forecast, by technique
7.1.4. Market volume and forecast, by application
7.1.5. Market volume and forecast, by end user
CHAPTER 8: COMPANY PROFILES, KEY MANUFACTURERS
8.1. Agilent Technologies, Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product type Portfolio
8.1.5. Business performance
8.2. General Electric Company (GE Healthcare)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Danaher Corporation (Beckman Coulter, Inc.)
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product type portfolio
8.3.5. Business performance
8.4. Evotec AG (Cyprotex)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Bioanalytical Systems, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. BRUKER CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. PerkinElmer Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.9. The Jackson Laboratory
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product Portfolio
8.9.4. Business performance
8.10. Thermo Fisher Scientific, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. BUSINESS PERFORMANCE
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017
3.3. Top player positioning, 2017
3.4. Porter’s five forces analysis
3.5. Government Regulations
3.6. Market Dynamics
3.6.1. Drivers
3.6.1.1. Surge in research and development activities in healthcare
3.6.1.2. Rise in adoption of vitro model
3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
3.6.1.4. Surge in adoption of early toxicity testing
3.6.2. Restraints
3.6.2.1. Limitations of preclinical testing
3.6.3. Opportunities
3.6.3.1. Technological advancement in the field of early toxicity testing
3.6.4. Impact Analyses
CHAPTER 4: EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
4.1. Overview
4.1.1. Market size and forecast
4.2. In Vivo
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by country
4.3. In Vitro
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by country
4.3.3. In Vitro Early Toxicity Testing Market, By Assay
4.3.3.1. Enzyme toxicity assays
4.3.3.1.1. Market size and forecast
4.3.3.2. Bacterial toxicity assays
4.3.3.2.1.1. Market size and forecast
4.3.3.3. Cell-Based ELISA and Western Blots
4.3.3.3.1.1. Market size and forecast
4.3.3.4. Tissues Culture Assays
4.3.3.4.1.1. Market size and forecast
4.3.3.5. Receptor Binding Assays
4.3.3.5.1.1. Market size and forecast
4.3.3.6. Other Assays
4.3.3.6.1.1. Market size and forecast
4.3.4. In Vitro Early Toxicity Testing Market, By Toxicity End-Points
4.3.4.1. Dermal Toxicity
4.3.4.1.1.1. Market size and forecast
4.3.4.1.1.2. Market size and forecast, by end user
4.3.4.2. Systemic toxicity
4.3.4.2.1.1. Market size and forecast
4.3.4.2.1.2. Market size and forecast, by end user
4.3.4.3. Carcinogenicity
4.3.4.3.1.1. Market size and forecast
4.3.4.4. Ocular toxicity
4.3.4.4.1.1. Market size and forecast
4.3.4.4.1.2. Market size and forecast, by end user
4.3.4.5. Skin sensitization and irritation
4.3.4.5.1.1. Market size and forecast
4.3.4.6. Genotoxicity
4.3.4.6.1.1. Market size and forecast
4.3.4.7. Neurotoxicity
4.3.4.7.1.1. Market size and forecast
4.3.4.8. Organ toxicity
4.3.4.8.1.1. Market size and forecast
4.3.4.9. Other toxicity endpoints
4.3.4.9.1.1. Market size and forecast
4.4. In Silico
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by country
CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Medical
5.2.1. Market size and forecast, by type
5.2.1.1. Examination
5.2.1.1.1. Market size and forecast
5.2.1.2. Surgical
5.2.1.2.1. Market size and forecast
5.2.2. Market size and forecast, by country
5.3. Non-Medical
5.3.1. Market size and forecast, by type
5.3.1.1. Food services
5.3.1.1.1. Market size and forecast
5.3.1.2. Clean Room
5.3.1.2.1. Market size and forecast
5.3.1.3. Industrial
5.3.1.3.1. Market size and forecast
5.3.2. Market size and forecast, by country
CHAPTER 6: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pharmaceutical Industry
6.2.1. Market size and forecast, by country
6.3. Diagnostics Industry
6.3.1. Market size and forecast, by country
6.4. Food Industry
6.4.1. Market size and forecast, by country
6.5. Chemicals Industry
6.5.1. Market size and forecast, by country
6.6. Cosmetic Industry
6.6.1. Market size and forecast, by country
6.7. Other Industries
6.7.1. Market size and forecast, by country
CHAPTER 7: EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY
7.1. Overview
7.1.1. Key market trends, growth factors, and opportunities
7.1.2. Market size and forecast, by country
7.1.2.1. Germany
7.1.2.1.1. Germany market size and forecast, by technique
7.1.2.1.2. Germany market size and forecast, by application
7.1.2.1.3. Germany market size and forecast, by end user
7.1.2.2. France
7.1.2.2.1. France market size and forecast, by technique
7.1.2.2.2. France market size and forecast, by application
7.1.2.2.3. France market size and forecast, by end user
7.1.2.3. UK
7.1.2.3.1. UK market size and forecast, by technique
7.1.2.3.2. UK market size and forecast, by application
7.1.2.3.3. UK market size and forecast, by end user
7.1.2.4. Rest of Europe
7.1.2.4.1. Rest of Europe market size and forecast, by technique
7.1.2.4.2. Rest of Europe market size and forecast, by application
7.1.2.4.3. Rest of Europe market size and forecast, by end user
7.1.3. Market size and forecast, by technique
7.1.4. Market volume and forecast, by application
7.1.5. Market volume and forecast, by end user
CHAPTER 8: COMPANY PROFILES, KEY MANUFACTURERS
8.1. Agilent Technologies, Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product type Portfolio
8.1.5. Business performance
8.2. General Electric Company (GE Healthcare)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Danaher Corporation (Beckman Coulter, Inc.)
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product type portfolio
8.3.5. Business performance
8.4. Evotec AG (Cyprotex)
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Bioanalytical Systems, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. BRUKER CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. PerkinElmer Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.9. The Jackson Laboratory
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product Portfolio
8.9.4. Business performance
8.10. Thermo Fisher Scientific, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. BUSINESS PERFORMANCE
LIST OF TABLES
TABLE 01. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 02. IN VIVO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 03. IN VITRO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 04. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)
TABLE 05. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)
TABLE 06. DERMAL TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 07. SYSTEMIC TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 08. OCULAR TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 09. IN SILICO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 10. EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 11. EUROPE EARLY TOXICITY MEDICAL MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 12. EUROPE EARLY TOXICITY MEDICAL MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 13. EUROPE EARLY TOXICITY NON-MEDICAL MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 14. EUROPE EARLY TOXICITY NON-MEDICAL MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 15. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 16. EUROPE EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 17. EARLY TOXICITY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 18. EARLY TOXICITY TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 19. EARLY TOXICITY TESTING MARKET FOR CHEMICALS INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 20. EARLY TOXICITY TESTING MARKET FOR COSMETIC INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 21. EARLY TOXICITY TESTING MARKET FOR OTEHR INDUSTRIES, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 22. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 23. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 24. GERMANY EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 25. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 26. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 27. FRANCE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 28. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 29. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 30. UK EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 31. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 32. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 33. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 34. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 35. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 36. EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATION, 2017–2025 (UNITS)
TABLE 37. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 (UNITS)
TABLE 38. AGILENT: COMPANY SNAPSHOT
TABLE 39. AGILENT: OPERATING SEGMENTS
TABLE 40. AGILENT: PRODUCT TYPE PORTFOLIO
TABLE 41. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 42. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 43. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 44. DANAHER: COMPANY SNAPSHOT
TABLE 45. DANAHER: OPERATING SEGMENTS
TABLE 46. DANAHER: PRODUCT TYPE PORTFOLIO
TABLE 47. EVOTEC: COMPANY SNAPSHOT
TABLE 48. EVOTEC: OPERATING SEGMENTS
TABLE 49. EVOTEC: PRODUCT PORTFOLIO
TABLE 50. BASI: COMPANY SNAPSHOT
TABLE 51. BASI: OPERATING SEGMENTS
TABLE 52. BASI: PRODUCT PORTFOLIO
TABLE 53. BRUKER: COMPANY SNAPSHOT
TABLE 54. BRUKER: OPERATING SEGMENTS
TABLE 55. BRUKER: PRODUCT PORTFOLIO
TABLE 56. PERKINELMER: COMPANY SNAPSHOT
TABLE 57. PERKINELMER: OPERATING SEGMENTS
TABLE 58. PERKINELMER: PRODUCT PORTFOLIO
TABLE 59. ENZO: COMPANY SNAPSHOT
TABLE 60. ENZO: OPERATING SEGMENTS
TABLE 61. ENZO: PRODUCT PORTFOLIO
TABLE 62. JAX: COMPANY SNAPSHOT
TABLE 63. JAX: PRODUCT PORTFOLIO
TABLE 64. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 65. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 66. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 01. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 02. IN VIVO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 03. IN VITRO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 04. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)
TABLE 05. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)
TABLE 06. DERMAL TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 07. SYSTEMIC TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 08. OCULAR TOXICITY MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 09. IN SILICO EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 10. EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 11. EUROPE EARLY TOXICITY MEDICAL MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 12. EUROPE EARLY TOXICITY MEDICAL MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 13. EUROPE EARLY TOXICITY NON-MEDICAL MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 14. EUROPE EARLY TOXICITY NON-MEDICAL MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 15. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 16. EUROPE EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 17. EARLY TOXICITY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 18. EARLY TOXICITY TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 19. EARLY TOXICITY TESTING MARKET FOR CHEMICALS INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 20. EARLY TOXICITY TESTING MARKET FOR COSMETIC INDUSTRY, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 21. EARLY TOXICITY TESTING MARKET FOR OTEHR INDUSTRIES, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 22. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 23. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 24. GERMANY EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 25. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 26. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 27. FRANCE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 28. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 29. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 30. UK EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 31. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 32. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 33. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATIONS, 2017–2025 ($MILLION)
TABLE 34. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 35. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 36. EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATION, 2017–2025 (UNITS)
TABLE 37. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 (UNITS)
TABLE 38. AGILENT: COMPANY SNAPSHOT
TABLE 39. AGILENT: OPERATING SEGMENTS
TABLE 40. AGILENT: PRODUCT TYPE PORTFOLIO
TABLE 41. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 42. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 43. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 44. DANAHER: COMPANY SNAPSHOT
TABLE 45. DANAHER: OPERATING SEGMENTS
TABLE 46. DANAHER: PRODUCT TYPE PORTFOLIO
TABLE 47. EVOTEC: COMPANY SNAPSHOT
TABLE 48. EVOTEC: OPERATING SEGMENTS
TABLE 49. EVOTEC: PRODUCT PORTFOLIO
TABLE 50. BASI: COMPANY SNAPSHOT
TABLE 51. BASI: OPERATING SEGMENTS
TABLE 52. BASI: PRODUCT PORTFOLIO
TABLE 53. BRUKER: COMPANY SNAPSHOT
TABLE 54. BRUKER: OPERATING SEGMENTS
TABLE 55. BRUKER: PRODUCT PORTFOLIO
TABLE 56. PERKINELMER: COMPANY SNAPSHOT
TABLE 57. PERKINELMER: OPERATING SEGMENTS
TABLE 58. PERKINELMER: PRODUCT PORTFOLIO
TABLE 59. ENZO: COMPANY SNAPSHOT
TABLE 60. ENZO: OPERATING SEGMENTS
TABLE 61. ENZO: PRODUCT PORTFOLIO
TABLE 62. JAX: COMPANY SNAPSHOT
TABLE 63. JAX: PRODUCT PORTFOLIO
TABLE 64. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 65. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 66. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. EUROPE EARLY TOXICITY TESTING MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, 2016-2018
FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2016-2018
FIGURE 05. TOP WINNING STRATEGIES: NATURE AND TYPE, 2016-2018
FIGURE 06. TOP PLAYER POSITIONING, 2017
FIGURE 07. MODERATE BARGANING POWER OF BUYERS
FIGURE 08. MODERATE BARGANING POWER OF SUPPLIERS
FIGURE 09. MODERATE THREAT OF SUBSTITUTION
FIGURE 10. LOW THREAT OF NEW ENTRANTS
FIGURE 11. HIGH COMPETITIVE RIVALRY
FIGURE 12. IMPACT ANALYSES, EUROPE EARLY TOXICITY TESTING MARKET
FIGURE 13. ENZYME TOXICITY ASSASYS MARKET, 2017–2025 ($MILLION)
FIGURE 14. BACTERIAL TOXICITY ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 15. CELL-BASED ELISA AND WESTERN BLOTS MARKET, 2017–2025 ($MILLION)
FIGURE 16. TISSUES CULTURE ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 17. RECEPTOR BINDING ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 18. OTHER ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 19. DERMAL TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 20. SYSTEMIC TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 21. CARCINOGENICITY MARKET, 2017–2025 ($MILLION)
FIGURE 22. OCULAR TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 23. SKIN SENSITIZATION AND IRRITATION MARKET, 2017–2025 ($MILLION)
FIGURE 24. GENOTOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 25. NEUROTOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 26. ORGAN TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 27. OTHER TOXICITY ENDPOINTS MARKET, 2017–2025 ($MILLION)
FIGURE 28. EXAMINATION MARKET, 2017–2025 ($MILLION)
FIGURE 29. SURGICAL MARKET, 2017–2025 ($MILLION)
FIGURE 30. FOOD SERVICES MARKET, 2017–2025 ($MILLION)
FIGURE 31. CLEAN ROOM MARKET, 2017–2025 ($MILLION)
FIGURE 32. INDUSTRIAL MARKET, 2017–2025 ($MILLION)
FIGURE 33. AGILENT: REVENUE, 2016–2018 ($MILLION)
FIGURE 34. AGILENT: REVENUE SHARE BY OPERATING SEGMENT, 2018 (%)
FIGURE 01. AGILENT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 02. GE HEALTHCARE: NET SALES, 2016–2018 ($MILLION)
FIGURE 03. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 04. GE HEALTHCARE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 05. DANAHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 06. DANAHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 07. DANAHER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 08. EVOTEC: NET SALES, 2016–2018 ($MILLION)
FIGURE 09. EVOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 10. EVOTEC: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 11. BASI: NET SALES, 2016–2018 ($MILLION)
FIGURE 12. BASI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 13. BASI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 14. BRUKER: NET SALES, 2016–2018 ($MILLION)
FIGURE 15. BRUKER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 16. BRUKER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 17. PERKINELMER: NET SALES, 2016–2018 ($MILLION)
FIGURE 18. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 19. PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. ENZO: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. ENZO: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 22. JAX: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 24. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 25. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY GEOGRAPHY, 2018 (%)
FIGURE 01. EUROPE EARLY TOXICITY TESTING MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, 2016-2018
FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2016-2018
FIGURE 05. TOP WINNING STRATEGIES: NATURE AND TYPE, 2016-2018
FIGURE 06. TOP PLAYER POSITIONING, 2017
FIGURE 07. MODERATE BARGANING POWER OF BUYERS
FIGURE 08. MODERATE BARGANING POWER OF SUPPLIERS
FIGURE 09. MODERATE THREAT OF SUBSTITUTION
FIGURE 10. LOW THREAT OF NEW ENTRANTS
FIGURE 11. HIGH COMPETITIVE RIVALRY
FIGURE 12. IMPACT ANALYSES, EUROPE EARLY TOXICITY TESTING MARKET
FIGURE 13. ENZYME TOXICITY ASSASYS MARKET, 2017–2025 ($MILLION)
FIGURE 14. BACTERIAL TOXICITY ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 15. CELL-BASED ELISA AND WESTERN BLOTS MARKET, 2017–2025 ($MILLION)
FIGURE 16. TISSUES CULTURE ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 17. RECEPTOR BINDING ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 18. OTHER ASSAYS MARKET, 2017–2025 ($MILLION)
FIGURE 19. DERMAL TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 20. SYSTEMIC TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 21. CARCINOGENICITY MARKET, 2017–2025 ($MILLION)
FIGURE 22. OCULAR TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 23. SKIN SENSITIZATION AND IRRITATION MARKET, 2017–2025 ($MILLION)
FIGURE 24. GENOTOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 25. NEUROTOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 26. ORGAN TOXICITY MARKET, 2017–2025 ($MILLION)
FIGURE 27. OTHER TOXICITY ENDPOINTS MARKET, 2017–2025 ($MILLION)
FIGURE 28. EXAMINATION MARKET, 2017–2025 ($MILLION)
FIGURE 29. SURGICAL MARKET, 2017–2025 ($MILLION)
FIGURE 30. FOOD SERVICES MARKET, 2017–2025 ($MILLION)
FIGURE 31. CLEAN ROOM MARKET, 2017–2025 ($MILLION)
FIGURE 32. INDUSTRIAL MARKET, 2017–2025 ($MILLION)
FIGURE 33. AGILENT: REVENUE, 2016–2018 ($MILLION)
FIGURE 34. AGILENT: REVENUE SHARE BY OPERATING SEGMENT, 2018 (%)
FIGURE 01. AGILENT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 02. GE HEALTHCARE: NET SALES, 2016–2018 ($MILLION)
FIGURE 03. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 04. GE HEALTHCARE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 05. DANAHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 06. DANAHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 07. DANAHER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 08. EVOTEC: NET SALES, 2016–2018 ($MILLION)
FIGURE 09. EVOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 10. EVOTEC: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 11. BASI: NET SALES, 2016–2018 ($MILLION)
FIGURE 12. BASI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 13. BASI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 14. BRUKER: NET SALES, 2016–2018 ($MILLION)
FIGURE 15. BRUKER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 16. BRUKER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 17. PERKINELMER: NET SALES, 2016–2018 ($MILLION)
FIGURE 18. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 19. PERKINELMER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. ENZO: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. ENZO: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 22. JAX: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 24. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 25. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY GEOGRAPHY, 2018 (%)
